Payment overview · 2025
General Payments
$1,751.13
76 reported records · 17 companies
Healthcare provider profile · identity verified
Sirisha Chalasani, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DUNNELLON, FL · NPI 1508849068
Verified facts
What the public records show
CMS Open Payments records show Sirisha Chalasani, MD received $1,751.13 in general payments during 2025 across 76 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $440.40 | 25.1% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $398.79 | 22.8% | 14 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $165.42 | 9.4% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $135.82 | 7.8% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $106.00 | 6.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $85.42 | 4.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $80.42 | 4.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.21 | 4.2% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $68.01 | 3.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $54.37 | 3.1% | 3 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.33 | 2.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.69 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $18.08 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.78 | 1.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.53 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.22 | 0.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.64 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,751.13 | 76 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $192.09 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $189.01 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $169.82 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $154.54 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $135.82 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $122.44 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $106.00 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $82.37 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $80.42 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $73.21 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.21 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $68.01 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.97 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $42.98 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $31.66 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 98 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
98 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
143 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 735 | 218 |
| Levothyroxine Sodium | Levothyroxine Sodium | 502 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 464 | 150 |
| Losartan Potassium | Losartan Potassium | 452 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 136 |
| Gabapentin | Gabapentin | 393 | 139 |
| Omeprazole | Omeprazole | 322 | 92 |
| Lisinopril | Lisinopril | 316 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 113 |
| Simvastatin | Simvastatin | 261 | 76 |
| Duloxetine Hcl | Duloxetine Hcl | 257 | 74 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 57 |
| Carvedilol | Carvedilol | 210 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 203 | 66 |
| Metformin Hcl | Metformin Hcl | 175 | 59 |
| Tramadol Hcl | Tramadol Hcl | 164 | 41 |
| Montelukast Sodium | Montelukast Sodium | 163 | 53 |
| Buspirone Hcl | Buspirone Hcl | 158 | 50 |
| Furosemide | Furosemide | 156 | 56 |
| Glimepiride | Glimepiride | 147 | 44 |
| Trazodone Hcl | Trazodone Hcl | 146 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 61 |
| Eliquis | Apixaban | 143 | 38 |
| Mirtazapine | Mirtazapine | 141 | 51 |
| Atenolol | Atenolol | 140 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 35 |
| Sertraline Hcl | Sertraline Hcl | 109 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 103 | 32 |
| Warfarin Sodium | Warfarin Sodium | 100 | 22 |
| Jardiance | Empagliflozin | 98 | 24 |
| Temazepam | Temazepam | 94 | 17 |
| Alprazolam | Alprazolam | 93 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 28 |
| Potassium Chloride | Potassium Chloride | 93 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 23 |
| Meloxicam | Meloxicam | 78 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 28 |
| Celecoxib | Celecoxib | 69 | 27 |
| Famotidine | Famotidine | 69 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 16 |
| Allopurinol | Allopurinol | 64 | 23 |
| Dexamethasone | Dexamethasone | 59 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 42 |
| Glipizide Er | Glipizide | 56 | 22 |
| Meclizine Hcl | Meclizine Hcl | 55 | 18 |
| Glipizide | Glipizide | 53 | 15 |
| Azithromycin | Azithromycin | 48 | 42 |
| Farxiga | Dapagliflozin Propanediol | 48 | 15 |
| Januvia | Sitagliptin Phosphate | 47 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | 12 |
| Alendronate Sodium | Alendronate Sodium | 45 | 15 |
| Lovastatin | Lovastatin | 45 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 14 |
| Sucralfate | Sucralfate | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 38 | 12 |
| Prednisone | Prednisone | 38 | 25 |
| Sulfasalazine | Sulfasalazine | 37 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | 14 |
| Cefdinir | Cefdinir | 32 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 15 |
| Propranolol Hcl | Propranolol Hcl | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 26 |
| Spironolactone | Spironolactone | 26 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | 16 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Droplet Insulin Syringe | Syrge-Ndl,ins 0.5 Ml Half Mark | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,751.13 · 76 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, FARXIGA, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VERQUVO, VRAYLAR, Veozah, Wegovy, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error